Cargando…
Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis
OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS). METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing–remitting multiple sclerosis (RRMS)...
Autores principales: | Abrahamyan, Sargis, Eberspächer, Bettina, Hoshi, Muna-Miriam, Aly, Lilian, Luessi, Felix, Groppa, Sergiu, Klotz, Luisa, Meuth, Sven G, Schroeder, Christoph, Grüter, Thomas, Tackenberg, Björn, Paul, Friedemann, Then-Bergh, Florian, Kümpfel, Tania, Weber, Frank, Stangel, Martin, Bayas, Antonios, Wildemann, Brigitte, Heesen, Christoph, Zettl, Uwe, Warnke, Clemens, Antony, Gisela, Hessler, Nicole, Wiendl, Heinz, Bittner, Stefan, Hemmer, Bernhard, Gold, Ralf, Salmen, Anke, Ruprecht, Klemens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361012/ https://www.ncbi.nlm.nih.gov/pubmed/32371533 http://dx.doi.org/10.1136/jnnp-2020-322941 |
Ejemplares similares
-
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021) -
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014) -
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021) -
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020) -
Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)